Artwork

Content provided by Chris Shulgan and Medcan CEO Shaun Francis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chris Shulgan and Medcan CEO Shaun Francis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

All About Semaglutide, Ozempic, Wegovy & Rybelsus

47:28
 
Share
 

Manage episode 372058329 series 2779508
Content provided by Chris Shulgan and Medcan CEO Shaun Francis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chris Shulgan and Medcan CEO Shaun Francis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Last year, Medcan director of weight management Dr. David Macklin predicted the diabetes medication semaglutide would be a game changer for those seeking help to lose weight. Now known by trade names like Ozempic, Wegovy and Rybelsus, today semaglutide is advertised on billboards and in TV commercials — and the hashtag has more than 330 million views on Tiktok. So we invited back Dr. Macklin to get his perspective on the medication, now that it’s actually on the market and being used by hundreds of thousands of people across North America. Joined by Medcan CMO Dr. Peter Nord, Dr. Macklin explains semaglutide’s benefits, side effects and costs — and describes what’s different about Medcan’s approach to weight management in the semaglutide era.

DISCLOSURE

In addition to his role at Medcan, Dr. Macklin helped to write the Canadian clinical guidelines for obesity. He also receives consulting fees, honoraria, and licensing fees from Novo Nordisk. Novo Nordisk is the manufacturer of semaglutide (trade name Ozempic).

Check out the episode webpage for links and more info.

  continue reading

105 episodes

Artwork
iconShare
 
Manage episode 372058329 series 2779508
Content provided by Chris Shulgan and Medcan CEO Shaun Francis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chris Shulgan and Medcan CEO Shaun Francis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Last year, Medcan director of weight management Dr. David Macklin predicted the diabetes medication semaglutide would be a game changer for those seeking help to lose weight. Now known by trade names like Ozempic, Wegovy and Rybelsus, today semaglutide is advertised on billboards and in TV commercials — and the hashtag has more than 330 million views on Tiktok. So we invited back Dr. Macklin to get his perspective on the medication, now that it’s actually on the market and being used by hundreds of thousands of people across North America. Joined by Medcan CMO Dr. Peter Nord, Dr. Macklin explains semaglutide’s benefits, side effects and costs — and describes what’s different about Medcan’s approach to weight management in the semaglutide era.

DISCLOSURE

In addition to his role at Medcan, Dr. Macklin helped to write the Canadian clinical guidelines for obesity. He also receives consulting fees, honoraria, and licensing fees from Novo Nordisk. Novo Nordisk is the manufacturer of semaglutide (trade name Ozempic).

Check out the episode webpage for links and more info.

  continue reading

105 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide